Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Summary

Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.

Timeline

Start

2022-04-01

Primary completion

2024-05-30

Completion

2025-04-30

Drugs

Indications